173 related articles for article (PubMed ID: 23836376)
21. New strategies in the discovery of novel non-camptothecin topoisomerase I inhibitors.
Sheng C; Miao Z; Zhang W
Curr Med Chem; 2011; 18(28):4389-409. PubMed ID: 21861816
[TBL] [Abstract][Full Text] [Related]
22. Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells.
Desai SD; Li TK; Rodriguez-Bauman A; Rubin EH; Liu LF
Cancer Res; 2001 Aug; 61(15):5926-32. PubMed ID: 11479235
[TBL] [Abstract][Full Text] [Related]
23. Molecular mechanism of the camptothecin resistance of Glu710Gly topoisomerase IB mutant analyzed in vitro and in silico.
Tesauro C; Morozzo della Rocca B; Ottaviani A; Coletta A; Zuccaro L; Arnò B; D'Annessa I; Fiorani P; Desideri A
Mol Cancer; 2013 Sep; 12(1):100. PubMed ID: 24004603
[TBL] [Abstract][Full Text] [Related]
24. Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance.
Wang LF; Ting CY; Lo CK; Su JS; Mickley LA; Fojo AT; Whang-Peng J; Hwang J
Cancer Res; 1997 Apr; 57(8):1516-22. PubMed ID: 9108454
[TBL] [Abstract][Full Text] [Related]
25. Molecular and cellular pharmacology of the novel noncamptothecin topoisomerase I inhibitor Genz-644282.
Sooryakumar D; Dexheimer TS; Teicher BA; Pommier Y
Mol Cancer Ther; 2011 Aug; 10(8):1490-9. PubMed ID: 21636699
[TBL] [Abstract][Full Text] [Related]
26. Camptothecin resistance involving steps subsequent to the formation of protein-linked DNA breaks in human camptothecin-resistant KB cell lines.
Beidler DR; Chang JY; Zhou BS; Cheng YC
Cancer Res; 1996 Jan; 56(2):345-53. PubMed ID: 8542590
[TBL] [Abstract][Full Text] [Related]
27. Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I.
Antony S; Jayaraman M; Laco G; Kohlhagen G; Kohn KW; Cushman M; Pommier Y
Cancer Res; 2003 Nov; 63(21):7428-35. PubMed ID: 14612542
[TBL] [Abstract][Full Text] [Related]
28. Camptothecins and topoisomerase I: a foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: importance of DNA replication, repair and cell cycle checkpoints.
Pommier Y
Curr Med Chem Anticancer Agents; 2004 Sep; 4(5):429-34. PubMed ID: 15379698
[TBL] [Abstract][Full Text] [Related]
29. Anticancer effect of SN-38 on colon cancer cell lines with different metastatic potential.
Wallin A; Svanvik J; Holmlund B; Ferreud L; Sun XF
Oncol Rep; 2008 Jun; 19(6):1493-8. PubMed ID: 18497955
[TBL] [Abstract][Full Text] [Related]
30. Janus-activated kinases and signal transducer and activator of transcription control tumor growth response to camptothecin in human colon cancer cells.
Yun HJ; Kim SY; Kwon YY; Kim CH; Kang CM; Kim EJ
Cancer Biol Ther; 2010 Aug; 10(4):354-61. PubMed ID: 20534983
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms of resistance to topoisomerase I-targeting drugs.
Rasheed ZA; Rubin EH
Oncogene; 2003 Oct; 22(47):7296-304. PubMed ID: 14576839
[TBL] [Abstract][Full Text] [Related]
32. Transcriptional targeting of human liver carboxylesterase (hCE1m6) and simultaneous expression of anti-BCRP shRNA enhances sensitivity of breast cancer cells to CPT-11.
Mishra MN; Vangara KK; Palakurthi S
Anticancer Res; 2014 Nov; 34(11):6345-51. PubMed ID: 25368234
[TBL] [Abstract][Full Text] [Related]
33. ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases.
Candeil L; Gourdier I; Peyron D; Vezzio N; Copois V; Bibeau F; Orsetti B; Scheffer GL; Ychou M; Khan QA; Pommier Y; Pau B; Martineau P; Del Rio M
Int J Cancer; 2004 May; 109(6):848-54. PubMed ID: 15027118
[TBL] [Abstract][Full Text] [Related]
34. Directed evolution to increase camptothecin sensitivity of human DNA topoisomerase I.
Scaldaferro S; Tinelli S; Borgnetto ME; Azzini A; Capranico G
Chem Biol; 2001 Sep; 8(9):871-81. PubMed ID: 11564555
[TBL] [Abstract][Full Text] [Related]
35. PARP-1-dependent RND1 transcription induced by topoisomerase I cleavage complexes confers cellular resistance to camptothecin.
Mouly L; Mamouni K; Gence R; Cristini A; Cherier J; Castinel A; Legrand M; Favre G; Sordet O; Monferran S
Cell Death Dis; 2018 Sep; 9(9):931. PubMed ID: 30209297
[TBL] [Abstract][Full Text] [Related]
36. RJT-101, a novel camptothecin derivative, is highly effective in the treatment of melanoma through DNA damage by targeting topoisomerase 1.
Lian C; Cao S; Zeng W; Li Y; Su J; Li J; Zhao S; Wu L; Tao J; Zhou J; Chen X; Peng C
Biochem Pharmacol; 2020 Jan; 171():113716. PubMed ID: 31751535
[TBL] [Abstract][Full Text] [Related]
37. A novel DNA topoisomerase I inhibitor with different mechanism from camptothecin induces G2/M phase cell cycle arrest to K562 cells.
Wu N; Wu XW; Agama K; Pommier Y; Du J; Li D; Gu LQ; Huang ZS; An LK
Biochemistry; 2010 Nov; 49(47):10131-6. PubMed ID: 21033700
[TBL] [Abstract][Full Text] [Related]
38. Acquired camptothecin resistance of human breast cancer MCF-7/C4 cells with normal topoisomerase I and elevated DNA repair.
Fujimori A; Gupta M; Hoki Y; Pommier Y
Mol Pharmacol; 1996 Dec; 50(6):1472-8. PubMed ID: 8967967
[TBL] [Abstract][Full Text] [Related]
39. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen.
Goldwasser F; Bae I; Valenti M; Torres K; Pommier Y
Cancer Res; 1995 May; 55(10):2116-21. PubMed ID: 7743511
[TBL] [Abstract][Full Text] [Related]
40. Silatecan DB-67 is a novel DNA topoisomerase I-targeted radiation sensitizer.
Chen AY; Shih SJ; Garriques LN; Rothenberg ML; Hsiao M; Curran DP
Mol Cancer Ther; 2005 Feb; 4(2):317-24. PubMed ID: 15713902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
